Heterocyclic Amide Kinase Inhibitors for Selective ATP Competition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective inhibitors of protein kinases to treat or prevent disease states associated with abnormal cell proliferation, requiring compounds that possess high affinity and selectivity for target kinases such as CHK1, CHK2, VEGF-R2, Pim-1, PDK-1, CDKs, and CDK/cyclin complexes, as well as receptor and non-receptor tyrosine kinases.
Innovation Solution
Development of a novel class of heterocyclic amide derivatives that function as protein kinase inhibitors, specifically designed to target various protein kinases, including CHK1, CHK2, VEGF-R2, Pim-1, PDK-1, CDKs, and tyrosine kinases, to treat proliferative diseases, inflammation, arthritis, neurological disorders, cardiovascular diseases, and viral or fungal infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ATP competitive small organic molecules are used as CDK inhibitors, then cell proliferation can be controlled, but selectivity and affinity for specific kinase targets may be insufficient
Solution Approach 1:
The patent applies local quality by designing heterocyclic amide compounds with specific functional groups positioned to interact with unique regions of the kinase active site. The heterocyclic ring system (e.g., pyridine, pyrimidine, triazole) provides localized electronic and steric properties that enhance binding to specific kinase residues, while the amide moiety forms hydrogen bonds with conserved backbone atoms, achieving both potency and selectivity through differentiated local interactions.
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters of the heterocyclic amide core, including ring size, heteroatom composition, substitution patterns, and side chain length. These parameter modifications allow fine-tuning of molecular properties such as basicity, hydrophobicity, and steric bulk, enabling optimization of binding affinity for specific kinases while maintaining selectivity against off-target enzymes.
2Adaptability or versatility
If broad-spectrum kinase inhibitors are used, then multiple disease targets can be addressed, but specificity for individual kinase pathways is reduced
Solution Approach 1:
The patent applies universality by designing a heterocyclic amide scaffold that can bind to multiple kinase families (CDKs, Src-family, tyrosine kinases, serine/threonine kinases) through a common mechanism of competing with ATP at the conserved active site. The core structure provides universal binding capability, while variable substituents allow adaptation to specific kinase isoforms, enabling one compound to address multiple disease-relevant targets.
Solution Approach 2:
The patent uses local quality to achieve selectivity within the multi-target framework by positioning specific functional groups on the heterocyclic ring to interact with unique amino acid residues in different kinase families. For example, basic side chains may target negatively charged residues in Src-family kinases, while hydrophobic groups may preferentially bind pockets in tyrosine kinases, allowing the same core scaffold to selectively modulate different pathways.
3Reliability
If existing CDK inhibitors like flavopiridol are used, then clinical trial data is available, but off-target effects and toxicity may occur
Solution Approach 1:
The patent applies taking out by extracting the essential pharmacophoric elements required for kinase inhibition (planar aromatic system, hydrogen bond donors/acceptors, basic nitrogen) from the flavopiridol structure, while removing or modifying groups responsible for off-target effects and toxicity. The heterocyclic amide core retains the ATP-competitive binding mechanism but with improved selectivity profile through deliberate structural simplification and optimization.
Solution Approach 2:
The patent employs structure-activity relationship (SAR) exploration with multiple heterocyclic amide variants, testing different ring systems (pyridine, pyrimidine, triazole, oxazole) and substituents to identify the minimum structural requirements for effective kinase inhibition. This iterative optimization process identifies the simplest effective structure that achieves the desired potency and selectivity, eliminating unnecessary complexity that could contribute to off-target effects.
Data Source
AI summary
The present invention relates to heterocyclic amide derivatives of Formula (I): Formula (I) wherein the variables are as defined in the specification. The present invention further relates to compositions comprising said heterocyclic amide derivatives of formula (I) and methods for using said heterocyclic amide derivatives of formula (I) for treating or preventing a disease or disorder related to the activity of a protein kinase, in particular, a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal infection.